In vivo imaging of serotonin transporter occupancy by means of SPECT and [123I]ADAM in healthy subjects administered different doses of escitalopram or citalopram

@article{Klein2006InVI,
  title={In vivo imaging of serotonin transporter occupancy by means of SPECT and [123I]ADAM in healthy subjects administered different doses of escitalopram or citalopram},
  author={Nikolas Klein and Julia Sacher and Thomas Geiss-Granadia and Trawat Attarbaschi and Nilufar Mossaheb and Rupert Lanzenberger and Christian Poetzi and Alexander Holik and Christoph Spindelegger and Susanne Asenbaum and Robert Dudczak and Johannes A Tauscher and Siegfried Kasper},
  journal={Psychopharmacology},
  year={2006},
  volume={188},
  pages={263-272}
}
Escitalopram is a dual serotonin reuptake inhibitor (SSRI) approved for the treatment of depression and anxiety disorders. It is the S-enantiomer of citalopram, and is responsible for the serotonin reuptake activity, and thus for its pharmacological effects. Previous studies pointed out that clinically efficacious doses of other SSRIs produce an occupancy of the serotonin reuptake transporter (SERT) of about 80% or more. The novel radioligand [123I]ADAM and single photon emission computer… CONTINUE READING